Xevinapant placebo, xevinapant clinical trials

EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)

This study looks at a new drug, xevinapant, given with radiotherapy for older patients with advanced head and neck cancer. We want to see if this combination helps more people live longer without their cancer coming back. It's a Phase II study, meaning we're testing its effectiveness and safety.